Figure 2.

MgiG improves cell viability following oxaliplatin exposure and protects liver cells by attenuating oxaliplatin-induced oxidative stress. (A) Viability of LO2 cells and of (B) HT-29 cells following oxaliplatin and MgiG treatment. (C) MDA levels in cells supernatants. (D) MDA levels in livers from experimental mice. (E) GSH levels in cells supernatants. (F) GSH levels in livers from experimental mice. (G) Cell viability of LO2 cells following oxaliplatin and MgiG treatment with the presence of supplementary 1 mM H₂O₂, or (H) 100 µM GSH in the medium. Data are presented as mean ± standard deviation (n=10 mice per group; n=3 for in vitro results). ^###P<0.001 compared with control; ^**P<0.01 and ^***P<0.001 compared with oxaliplatin alone. MgiG, magnesium isoglycyrrhizinate; MDA, malondialdehyde; GSH, glutathione; Oxa, oxaliplatin.